Literature DB >> 2766521

Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm.

G W He1, F L Rosenfeldt, B F Buxton, J A Angus.   

Abstract

Perioperative spasm of the internal mammary artery (IMA) may occur after coronary artery bypass surgery. To establish the most appropriate dilator agent, we tested the reactivity of ring segments of human IMA in organ baths to various constrictor and dilator agents. We found that the thromboxane mimetic U46619 was the most potent IMA constrictor agent, followed by norepinephrine, serotonin, phenylephrine, and potassium chloride (K+). In K+- or U46619-precontracted IMA, glyceryl trinitrate and papaverine caused full relaxation. In K+-precontracted arteries, nifedipine, verapamil, and diltiazem caused full relaxation, but nifedipine was 15-fold more potent than the other calcium antagonists. In contrast, pretreatment of vessels with glyceryl trinitrate failed to alter subsequent contraction to U46619 or K+ while nifedipine pretreatment abolished subsequent contraction to K+ and reduced sensitivity of the IMA to U46619. We conclude that perioperative IMA spasm could be treated with the rapid-onset, nonspecific, vasodilator glyceryl trinitrate, but for prophylaxis of IMA spasm, calcium antagonists or specific receptor antagonists should be tested in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766521

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Effects of potassium channel opener KRN4884 on human conduit arteries used as coronary bypass grafts.

Authors:  Z Ren; S Floten; A Furnary; M Liu; H Gately; J Swanson; A Ahmad; A P Yim; G W He
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  A functional and histopathological comparison of proximal and distal saphenous vein contractility and morphology.

Authors:  Ilhan Golbasi; Arda Tasatargil; Nazif Hikmet Aksoy; Gulay Sadan; Edibe Karasu; Cengiz Turkay; Omer Bayezid
Journal:  Tex Heart Inst J       Date:  2005

3.  Arterial grafts: clinical classification and pharmacological management.

Authors:  Guo-Wei He
Journal:  Ann Cardiothorac Surg       Date:  2013-07

4.  Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle.

Authors:  F Stanke; P Devillier; D Bréant; O Chavanon; C Sessa; G Bricca; G Bessard
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

5.  Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery.

Authors:  T J Batchelor; J R Sadaba; A Ishola; P Pacaud; C M Munsch; D J Beech
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

6.  Comparison of the vasorelaxant effect of nitroprusside and nitroglycerin in the human radial artery in vitro.

Authors:  G W He; C Q Yang
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

7.  Inhibition of vasoconstriction by AJ-2615, a novel calcium antagonist with alpha(1)-adrenergic receptor blocking activity in human conduit arteries used as bypass grafts.

Authors:  M H Liu; S H Floten; Q Yang; G W He
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

8.  Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery.

Authors:  G W He; C Q Yang
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

9.  S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery.

Authors:  N Sogo; C Campanella; D J Webb; I L Megson
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

10.  Arterial segments as microvascular interposition grafts in venous anastomosis in digital replantations.

Authors:  Shiv Shankar Saha; Anurag Pandey; Chirayu Parwal
Journal:  Indian J Plast Surg       Date:  2015 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.